Identification of Therapeutic Targets in Autism Spectrum Disorder through CHD8-Notch Pathway Interaction Analysis.

Scientists studied how changes in a specific gene called CHD8 might contribute to autism. They used computer analysis to identify seven important genes that work together in brain development. Two genes (IGF2 and CXCR4) appeared particularly important and could potentially be targets for new treatments. The research also identified some existing medications that might help, though more studies are needed to confirm these findings.

This bioinformatics study analyzed genomic data to investigate how mutations in the CHD8 gene contribute to autism spectrum disorder. Researchers examined gene expression patterns in CHD8-deficient samples and identified interactions with the Notch signaling pathway. Through computational analysis, they identified seven key genes (IGF2, FN1, CXCR4, COL11A1, ITGA6, LOX, and FBN2) that may play important roles in autism development. The study suggests these genes are involved in brain development and cellular communication processes.

Researchers also identified potential therapeutic compounds (AMD3100 and IGF-1R inhibitors) and regulatory molecules (miRNAs) that could influence these genes, offering new insights into potential treatment approaches for autism.

The identified genes may serve as biomarkers for autism diagnosis and potential therapeutic targets. The study suggests existing drugs (AMD3100, IGF-1R inhibitors) could be investigated for autism treatment. However, extensive validation studies and clinical trials would be needed before any clinical applications.

This is a computational analysis using existing datasets without experimental validation. Sample sizes were not reported. The findings represent bioinformatics predictions that require laboratory and clinical validation before clinical application.

Autism Spectrum Disorder (ASD) is a complex neurodevelopmental disorder with a rising global prevalence. Mutations in the CHD8 gene have been implicated in ASD, yet the underlying molecular mechanisms remain insufficiently understood. We analyzed transcriptomic data from the CHD8A and CHD8B allelic deletion sample dataset GSE236993 to identify differentially expressed genes (DEGs). We intersected these DEGs with genes related to the Notch signaling pathway and performed functional enrichment analyses, including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment, as well as protein-protein interaction (PPI) analyses, to identify key genes.

These key genes were validated using the CHD8-deficient sample dataset GSE85417, resulting in the identification of seven common key genes. We then constructed drug-gene interaction networks and microRNA (miRNA) regulatory networks to further elucidate the mechanisms by which CHD8 impacts ASD. Seven hub genes-IGF2, FN1, CXCR4, COL11A1, ITGA6, LOX, and FBN2-were identified, all involved in the Notch signaling pathway and playing significant roles in neurodevelopment and extracellular matrix regulation. Among these, IGF2 and CXCR4 were particularly crucial in ASD pathogenesis, suggesting their potential as diagnostic biomarkers and therapeutic targets.

MiRNA regulatory network analysis revealed several miRNAs that may modulate these hub genes, offering new insights into ASD pathogenesis. Drug-gene interaction analysis suggested possible therapeutic small-molecule compounds, such as AMD3100 and IGF-1R inhibitors. Our multi-level bioinformatics analysis identified key genes and regulatory networks potentially involved in ASD associated with CHD8 deficiency. These findings enhance the understanding of ASD's molecular mechanisms and highlight potential therapeutic targets, paving the way for future diagnostic and treatment strategies.